Cancer - APAL2020SC: Pediatric Acute Leukemia (PedAL) Screening Trial – Developing New Therapies for Relapsed Leukemias
Condition or Therapy:
Relapsed/refractory: acute myeloid leukemia, myeloid sarcoma, mixed phenotype acute leukemia, therapy-related acute myeloid leukemia, and B or T acute lymphoblastic leukemia
What is the goal of this study?
This study is a screening trial. The goal of this study is to genetically screen patients and find trials for which patients will be eligible. This study will screen patients for molecular diagnostics, genomic profiling and more. Based on these results, patients may be eligible to enroll in a trial that will provide treatment. This study is also creating a comprehensive registry in children and young adults with recurrent/refractory leukemia.
Who can join the study?
This study may be a good fit for children and young adults who:
- Are less than 22 years of age
- Have relapsed/refractory AML or subtypes of ALL
You can read more about the eligibility criteria for this study on clinicaltrials.gov.
Researchers use many other factors to decide whether a patient can take part in a study (inclusion criteria) or cannot take part (exclusion criteria). The study team at Seattle Children’s can explain what these factors mean for your child.
What will happen if my child takes part in this study?
Participants in this study will be asked to donate specimens to begin the genetic screening. After the genetic screening is complete, researchers will determine if participants are eligible to enroll in a trial that will provide treatment. If a participant is not eligible for a trial, the researchers would still like to follow the participant for follow-up.
Who can I contact for more information?
Please email the research coordinator or call the study team at (206) 987-2106 for more information about this study.